このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

小児および若年成人の脳腫瘍治療におけるフィメピノスタット (PNOC016)

2026年10月28日 更新者:Sabine Mueller, MD, PhD

新たにびまん性内在性橋グリオーマ(DIPG)、再発性髄芽腫、または再発性高悪性度グリオーマ(HGG)と診断された小児および若年成人におけるフィメピノスタットのターゲット検証研究

This trial studies how well fimepinostat works in treating patients with newly diagnosed diffuse intrinsic pontine glioma, or medulloblastoma, or high-grade glioma that have come back. Fimepinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

調査の概要

詳細な説明

PRIMARY OBJECTIVES:

I. To confirm penetration of fimepinostat across the blood brain barrier (BBB) in children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG), recurrent medulloblastoma, or recurrent high-grade glioma (HGG) by measuring concentration of fimepinostat and metabolite in primary tumor tissue.

EXPLORATORY OBJECTIVES:

I. To assess pharmacokinetics (PK) of fimepinostat in plasma and tumor tissue of children and young adults with newly diagnosed DIPG, recurrent medulloblastoma, or recurrent HGG.

II. To assess pharmacodynamics (PD) of fimepinostat in children and young adults with newly diagnosed DIPG, recurrent medulloblastoma, or recurrent HGG as measured by phosphorylation and acetylation in tumor tissue.

III. To correlate acetylation and phosphorylation in tumor tissue with tissue and plasma PK levels.

IV. To assess the safety and tolerability of fimepinostat in children and young adults with newly diagnosed DIPG, recurrent medulloblastoma, or recurrent HGG.

V. To assess preliminary efficacy of fimepinostat given as monotherapy after surgery in children and young adults with newly diagnosed DIPG, recurrent medulloblastoma, or recurrent HGG, as based on progression-free survival (PFS) and objective response rate (ORR) as appropriate.

OUTLINE:

Patients receive fimepinostat orally (PO) once daily (QD) on days -2 to 0. Within 2 hours of receiving fimepinostat on day 0, patients undergo tumor resection.

MAINTENANCE PHASE: Patients receive fimepinostat by mouth, once daily for days 1-5 each week. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity for up to 12 months from the time treatment begins. Should patients continue to derive clinical benefit, and not experience excess toxicity or progression, patients can continue to receive drug for up to 24 months or longer pending discussion with study chairs and study sponsor.

After completion of study treatment, patients are followed up at 30 days, then every 3 months for up to 5 years.

研究の種類

介入

入学 (実際)

30

段階

  • 初期フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • California
      • Los Angeles、California、アメリカ、90027
        • Children's Hospital Los Angeles (CHLA)
      • San Diego、California、アメリカ、92123
        • Rady Children's Hospital
      • San Francisco、California、アメリカ、94143
        • University of California, San Francisco
    • District of Columbia
      • Washington D.C.、District of Columbia、アメリカ、20010
        • Children's National Medical Center
    • Florida
      • Gainesville、Florida、アメリカ、32611
        • University of Florida
    • Illinois
      • Chicago、Illinois、アメリカ、60611
        • Lurie Children's Hospital of Chicago
    • Maryland
      • Baltimore、Maryland、アメリカ、21231
        • Johns Hopkins Hospital
    • Massachusetts
      • Boston、Massachusetts、アメリカ、02215
        • Dana Farber Cancer Institute
    • Michigan
      • Ann Arbor、Michigan、アメリカ、48109
        • University of Michigan Hospital
    • Minnesota
      • Minneapolis、Minnesota、アメリカ、55404
        • Children's Minnesota Research Institute
    • Missouri
      • St Louis、Missouri、アメリカ、63110
        • Washington University in St Louis
    • Ohio
      • Columbus、Ohio、アメリカ、43205
        • Nationwide Children's
    • Oregon
      • Portland、Oregon、アメリカ、97239
        • Oregon Health and Science University
    • Pennsylvania
      • Philadelphia、Pennsylvania、アメリカ、19146
        • Children's Hospital of Philadelphia (CHOP)
    • Tennessee
      • Memphis、Tennessee、アメリカ、38105
        • St. Jude Children's Research Hospital
    • Texas
      • Houston、Texas、アメリカ、77030
        • Texas Children's Hospital
    • Utah
      • Salt Lake City、Utah、アメリカ、84113
        • University of Utah, Children's Primary
    • Washington
      • Seattle、Washington、アメリカ、98105
        • Seattle Children's Hospital
    • Canton of Zurich
      • Zurich、Canton of Zurich、スイス、8032
        • The University Children's Hospital in Zurich

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

3年~39年 (子、大人)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Patients must have one of the following histologically confirmed diagnoses (histologic confirmation from initial diagnosis acceptable, as appropriate):

    • Stratum A: Newly diagnosed diffuse intrinsic pontine glioma (WHO grade II-IV) - this stratum does not require tissue confirmation at time of enrollment, but diagnostic confirmation will be required to continue on study after biopsy. Patients with newly diagnosed DIPG will be eligible to enroll before or after standard of care radiation, but must be eligible for a biopsy. Newly diagnosed DIPG stratum should not have received prior therapy before the initiation of fimepinostat, with the exception of those patients who received temozolomide during radiation therapy or who previously received radiation as per standard of care and have not yet undergone a biopsy. All patients who have received therapy other than radiation and temozolomide should be discussed with study chair(s) prior to enrollment. Patients enrolling after standard of care radiation must be enrolled within 14 weeks of completion of radiotherapy.

    • Stratum B: Recurrent medulloblastoma (WHO grade IV), any molecular subtype

    • Stratum C: Recurrent high-grade glioma (HGG), including anaplastic astrocytoma (WHO grade III) and glioblastoma (WHO grade IV)

      • Stratum B & C: Patients in the recurrent medulloblastoma or recurrent HGG arm can have locally recurrent or disseminated disease, provided resection/biopsy would still be clinically indicated. Disseminated disease can be diagnosed by imaging or Cerebrospinal fluid (CSF) cytology. Recurrent DIPG will be eligible for stratum C; however, eligibility requires biopsy/resection is feasible in a region of tumor outside of the pons (i.e. cerebellar extension or new metastatic site). These patients should be discussed with study chair(s) prior to enrollment
  • Patients must be able to swallow intact fimepinostat capsules or mini-tabs without chewing or crushing

  • Patients must have body surface area (BSA) >= 0.5 m^2

  • Patients must undergo tumor tissue collection as part of their standard of care

    • Minimum possible tissue collected must be equivalent to about 4-6 stereotactic core biopsies
  • Prior Therapy: Patients in the medulloblastoma and HGG strata will be allowed to have undergone prior therapy including surgery, chemotherapy, and radiation therapy. Patients in the newly diagnosed DIPG stratum should not have received prior therapy before the initiation of fimepinostat, with the exception of those patients who received temozolomide during radiation therapy or who previously received radiation as per standard of care and have not yet undergone a biopsy. All patients who have received therapy other than radiation and temozolomide should be discussed with study chair(s) prior to enrollment. Patients must have fully recovered from acute side effects related to previous anti-cancer therapies. Patients undergoing radiation during protocol therapy will not be permitted to receive other concomitant agents with radiation and pending initiation of maintenance with fimepinostat

    • Myelosuppressive chemotherapy: At least 21 days after last dose of myelosuppressive chemotherapy (42 days if prior nitrosourea)

    • Hematopoietic growth factors: At least 14 days after last dose of a long-acting growth factor or 7 days after short-acting growth factor or beyond time during which adverse events are known to occur

    • Biologic (anti-neoplastic agent): At least 7 days after last dose of a biologic agent or beyond time during which adverse events are known to occur

    • Monoclonal antibodies: At least 21 days after last dose of monoclonal antibody

    • Radiotherapy:

      • At least 2 weeks after local palliative radiotherapy (XRT)
      • At least 3 months from craniospinal XRT, or XRT to > 50% pelvis
    • Surgery:

      • At least 21 days from major surgery (biopsy and central line placement/removal are not considered major)
  • Corticosteroids: Subjects who are receiving dexamethasone must be on a stable or decreasing dose for at least 7 days prior to enrollment

  • Peripheral absolute neutrophil count (ANC) >= 1000/mm^3

  • Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)

  • Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 milliliters (mL)/minute (min)/1.73 m^2 or

  • A serum creatinine based on age/gender as follows:

    • Age: Maximum Serum Creatinine (mg/dL)
    • 3 to < 6 years: 0.8 (male), 0.8 (female)
    • 6 to < 10 years: 1 (male), 1 (female)
    • 10 to < 13 years: 1.2 (male), 1.2 (female)
    • 13 to < 16 years: 1.5 (male), 1.4 (female)
    • >= 16 years: 1.7 (male), 1.4 (female)
  • Bilirubin (sum of conjugated + unconjugated) =< 1.5 x upper limit of normal (ULN) for age

  • Serum glutamate pyruvate transaminase (SGPT)/alanine aminotransferase (ALT) =< 110 U/L

  • Serum albumin >= 2 g/dL

  • Neurologic function:

    • Subjects with seizure disorder may be enrolled if well controlled
  • Gastrointestinal function:

    • Diarrhea < grade 2 by Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0
  • Metabolic function:

    • Non-fasting glucose < 125 mg/dL without the use of antihyperglycemic agents

      • If non-fasting glucose > 125 mg/dL, a fasting glucose should be done. If fasting glucose =< 160 mg/dL without the use of antihyperglycemic agents, patient will meet adequate metabolic function criteria
  • Cardiac function: corrected QT (QTc) < 480 msec

  • The effects of fimepinostat on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and 30 days after completion of fimepinostat administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately

  • A legal parent/guardian or patient must be able to understand, and willing to sign, a written informed consent and assent document, as appropriate

Exclusion Criteria:

  • Subjects who have not recovered from acute adverse events due to therapeutic agents administered more than 4 weeks earlier
  • Patients must not have received prior therapy with single-agent or combination histone deacetylase (HDAC) and Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) inhibitors
  • Subjects who are receiving any other investigational agent
  • History of allergic reaction to compounds of similar chemical or biological composition to fimepinostat
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situation that would limit compliance with study requirements
  • Patients with active human immunodeficiency virus (HIV) infection and with potential life-threatening consequences associated with immune-suppressive therapy
  • Patients with history of type 1 or 2 diabetes mellitus
  • Patients with gastrointestinal condition that could interfere with absorption or metabolism of fimepinostat

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Treatment (fimepinostat, tumor resection)

Patients receive fimepinostat by mouth once daily, on Days -2 to 0. Within 2 hours of receiving fimepinostat on Day 0, patients undergo tumor resection or biopsy as part of their standard of care.

MAINTENANCE PHASE: Patients receive fimepinostat by mouth, once daily for days 1-5 each week. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity for up to 12 months from the time treatment begins. Should patients continue to derive clinical benefit, and not experience excess toxicity or progression, patients can continue to receive drug for up to 24 months or longer pending discussion with study chairs and study sponsor.

Undergo surgery

Fimepinostat capsules

他の名前:
  • CUDC-907

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Penetration of fimepinostat across the blood brain barrier (BBB)
時間枠:During surgery or biopsy

Will be analyzed using descriptive statistics from results of fimepinostat concentrations measured within the tumor tissue collected at the time of a standard of care surgery or biopsy. Within each strata, Simon's two-stage design will be used.

During surgery or biopsy

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Sabine Mueller, MD, PhD、University of California, San Francisco

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2019年8月7日

一次修了 (実際)

2022年10月31日

研究の完了 (実際)

2026年10月28日

試験登録日

最初に提出

2019年3月26日

QC基準を満たした最初の提出物

2019年3月26日

最初の投稿 (実際)

2019年3月28日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月2日

QC基準を満たした最後の更新が送信されました

2026年10月28日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Individual participant data after de-identification

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する